He cites FDA counts of 990 adverse event reports tied to compounded semaglutide and over 730 for compounded tirzepatide, and warns about research-use-only sellers.
Recap by typeshit. Full story at Newsweek.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
As Ozempic, Wegovy and Mounjaro spread in clinics, OncoDaily covers the growing research interest in how these drugs relate to cancer.
A new 'In Discussion With' episode featuring Sehar Shahid on the pace of weight loss with GLP-1 receptor agonists. Few details shared beyond the topic.
Loading…